

# ABROCITINIB/DUPILUMAB For Atopic Dermatitis SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by Alberta government sponsored drug programs.

PATIENT INFORMATION				COVERAGE TYPE	
LAST NAME	FIRST NAME	INITIAL	<input type="checkbox"/> Alberta Blue Cross <input type="checkbox"/> Alberta Human Services <input type="checkbox"/> Other _____		
BIRTH DATE (YYYY-MM-DD)	ALBERTA PERSONAL HEALTH NUMBER				
ADDRESS	CITY	PROV	POSTAL CODE	ID/CLIENT/COVERAGE NUMBER	

PRESCRIBER INFORMATION					
PRESCRIBER LAST NAME	FIRST NAME	INITIAL	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION		
ADDRESS			<input type="checkbox"/> CPSA	<input type="checkbox"/> ACO	REGISTRATION NUMBER
			<input type="checkbox"/> CARNA	<input type="checkbox"/> ADA+C	
CITY, PROVINCE			PHONE	FAX	
POSTAL CODE			FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED		

**Please provide the following information for ALL requests**

<b>Requested drug</b>	<input type="checkbox"/> Abrocitinib (e.g. Cibinqo)	<input type="checkbox"/> Dupilumab (e.g. Dupixent)
<b>Diagnosis</b>	<b>Dosage and frequency</b>	<b>Current weight (kg)</b>
<input type="checkbox"/> Moderate to severe atopic dermatitis <input type="checkbox"/> Other (please specify) _____		
<b>Combination therapy</b>	Will the requested drug be used in combination with phototherapy or immunomodulating drugs	<input type="checkbox"/> Yes <input type="checkbox"/> No
For patients new to coverage but currently maintained on the requested drug, provide the treatment start date _____		

**Please provide the following pre-treatment information for NEW requests for treatment-naïve and treatment-experienced patients**

- 1) **Pre-treatment** Investigator's Global Assessment (IGA) score \_\_\_\_\_ and date \_\_\_\_\_
- 2) **Pre-treatment** Eczema Area and Severity Index (EASI) score \_\_\_\_\_ and date \_\_\_\_\_
- 3) **Previous medications and therapies utilized**—check all that apply and indicate dose, duration and response to each, or indicate contraindication, if applicable
  - Topical corticosteroid \_\_\_\_\_
  - Topical calcineurin inhibitor \_\_\_\_\_
  - Conventional systemic immunomodulatory drugs (agents must be steroid sparing. For dupilumab, please specify **2**)
  - Agent #1: \_\_\_\_\_
  - Agent #2: \_\_\_\_\_
  - Phototherapy \_\_\_\_\_

**Please provide the following information for RENEWAL requests and INITIAL requests for treatment experienced patients**

- 1) **Current** EASI score \_\_\_\_\_ and date \_\_\_\_\_

**Additional information relating to request**

---

PRESCRIBER'S SIGNATURE	DATE (YYYY-MM-DD)	Please forward this request to <b>Alberta Blue Cross, Clinical Drug Services</b> 10009 108 Street NW, Edmonton, Alberta T5J 3C5 FAX <b>780-498-8384</b> in Edmonton • <b>1-877-828-4106</b> toll free all other areas
------------------------	-------------------	--

**ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST.**